Cargando…

Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033

BACKGROUND: EORTC study 22033–26033 showed no difference in progression-free survival between high-risk low-grade glioma receiving either radiotherapy (RT) or temozolomide (TMZ) chemotherapy alone as primary treatment. Considering the potential long-term deleterious impact of RT on memory functionin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klein, Martin, Drijver, A Josephine, van den Bent, Martin J, Bromberg, Jacolien C, Hoang-Xuan, Khê, Taphoorn, Martin J B, Reijneveld, Jaap C, Ben Hassel, Mohamed, Vauleon, Elodie, Eekers, Daniëlle B P, Tzuk-Shina, Tzahala, Lucas, Anna, Freixa, Salvador Villà, Golfinopoulos, Vasilis, Gorlia, Thierry, Hottinger, Andreas F, Stupp, Roger, Baumert, Brigitta G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099470/ https://www.ncbi.nlm.nih.gov/pubmed/33130890 http://dx.doi.org/10.1093/neuonc/noaa252

Ejemplares similares

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma: A randomized phase III Intergroup study by EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033)
por: Baumert, Brigitta G., et al.
Publicado: (2016)

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033
por: Bady, Pierre, et al.
Publicado: (2018)

Evaluation of the Hippocampal Normal Tissue Complication Model in a Prospective Cohort of Low Grade Glioma Patients—An Analysis Within the EORTC 22033 Clinical Trial
por: Jaspers, Jaap, et al.
Publicado: (2019)

The Clinical Significance of Ependymal Enhancement at Presentation in Patients with Malignant Glioma
por: Kaidar-Person, Orit, et al.
Publicado: (2015)

Survival impact of the time gap between surgery and chemo-radiotherapy in Glioblastoma patients
por: Zur, Inbar, et al.
Publicado: (2020)

Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients
por: Dirven, Linda, et al.
Publicado: (2021)

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform
por: Morfouace, M., et al.
Publicado: (2022)

Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period
por: Coomans, Marijke B, et al.
Publicado: (2022)

Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951
por: Idbaih, Ahmed, et al.
Publicado: (2010)

Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors
por: Lassman, Andrew B., et al.
Publicado: (2022)

Is the EORTC QLQ‐C30 emotional functioning scale appropriate as an initial screening measure to identify brain tumour patients who may possibly have a mood disorder?
por: Oort, Quirien, et al.
Publicado: (2022)

Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?
por: Coomans, Marijke B, et al.
Publicado: (2019)

Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients
por: Coomans, Marijke B, et al.
Publicado: (2020)

Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling
por: Coomans, Marijke B, et al.
Publicado: (2020)

Development and psychometric evaluation of item banks for memory and attention – supplements to the EORTC CAT Core instrument
por: Rogge, AA, et al.
Publicado: (2023)

26033 Exacerbation and appearance of dermatosis during COVID-19 quarantine period in Bogotá, Colombia: A descriptive study of the psychological impairments
por: Castillo Molina, David A., et al.
Publicado: (2021)

International clinical trials setting for rare cancers: organisational and regulatory constraints—the EORTC perspective
por: Shash, Emad, et al.
Publicado: (2013)

Development of an EORTC questionnaire measuring instrumental activities of daily living (IADL) in patients with brain tumours: phase I–III
por: Oort, Quirien, et al.
Publicado: (2021)

Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: comprehensive molecular analysis of EORTC 22042–26042
por: Maas, Sybren L. N., et al.
Publicado: (2023)

Psychometric evaluation of an item bank for computerized adaptive testing of the EORTC QLQ-C30 cognitive functioning dimension in cancer patients
por: Dirven, Linda, et al.
Publicado: (2017)

EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe
por: de Rojas, Teresa, et al.
Publicado: (2019)

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: Van Den Bent, Martin, et al.
Publicado: (2020)

A Web-Based Lifestyle Intervention Aimed at Improving Cognition in Patients With Cancer Returning to Work in an Outpatient Setting: Protocol for a Randomized Controlled Trial
por: Drijver, A Josephine, et al.
Publicado: (2021)

Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: van den Bent, Martin, et al.
Publicado: (2020)

Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
por: Kessler, Tobias, et al.
Publicado: (2023)

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study
por: Sleijfer, S, et al.
Publicado: (2012)

Standards of care and novel approaches in the management of glioblastoma multiforme
por: Hottinger, Andreas F., et al.
Publicado: (2014)

Tumor treating fields: a novel treatment modality and its use in brain tumors
por: Hottinger, Andreas F., et al.
Publicado: (2016)

Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma
por: Tesileanu, C Mircea S, et al.
Publicado: (2021)

Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group
por: Stupp, R., et al.
Publicado: (2011)

Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23
por: Hau, Peter, et al.
Publicado: (2021)

Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101
por: Caramanna, Ivan, et al.
Publicado: (2022)

First results of the EORTC-SPECTA/Arcagen study exploring the genomics of rare cancers in collaboration with the European reference network EURACAN
por: Morfouace, Marie, et al.
Publicado: (2020)

Translation and validation of the EORTC brain cancer module (EORTC QLQ-BN20) for use in Iran
por: Khoshnevisan, Alireza, et al.
Publicado: (2012)

Development of an item bank for the EORTC Role Functioning Computer Adaptive Test (EORTC RF-CAT)
por: Gamper, Eva-Maria, et al.
Publicado: (2016)

Interpreting Within-Patient Changes on the EORTC QLQ-C30 and EORTC QLQ-LC13
por: Coon, Cheryl D., et al.
Publicado: (2022)

The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study
por: Mauer, M, et al.
Publicado: (2007)

Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group.
por: Fosså, S. D., et al.
Publicado: (1995)

Dutch utility weights for the EORTC cancer-specific utility instrument: the Dutch EORTC QLU-C10D
por: Jansen, Femke, et al.
Publicado: (2021)

Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial
por: Ediebah, D E, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_lt3j6k0anj9m6c5tjda37imbsq